Indication

Adjunct therapy for irritable bowel syndrome

Irritable bowel syndrome is a chronic disorder of gut-brain interaction that predominantly affects the gastrointestinal tract in adults, with a higher prevalence observed in females. Read more about Adjunct therapy for irritable bowel syndrome

19 drugs 18 manufacturers

Advertisement

Drugs that treat it

Common Adjunct therapy for irritable bowel syndrome therapies.

Showing 10–18 of 19 drugs

Filter & compare in the drug finder →Opens the drug finder with Adjunct therapy for irritable bowel syndrome preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Adjunct therapy for irritable bowel syndrome.

Irritable bowel syndrome is a chronic disorder of gut-brain interaction that predominantly affects the gastrointestinal tract in adults, with a higher prevalence observed in females.

It is clinically characterized by recurrent abdominal pain related to defecation, accompanied by changes in stool frequency or form, manifesting as constipation-predominant, diarrhea-predominant, or mixed bowel habit patterns.

The underlying pathophysiology involves dysregulated bidirectional communication along the brain-gut axis, gastrointestinal motility disturbances, visceral hypersensitivity, low-grade mucosal inflammation, altered intestinal permeability, and gut microbiome dysbiosis.

In the context of adjunct therapy, pharmacological interventions are utilized as supplemental, secondary measures alongside standard lifestyle, dietary, or primary symptom-directed therapies to control refractory manifestations such as acute visceral hyperalgesia, abdominal cramping, or persistent motility abnormalities.

Personalize your experience

Follow Adjunct therapy for irritable bowel syndrome and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it